Cwm, LLC Intra Cellular Therapies, Inc. Transaction History

Cwm, LLC

$24.1 Billion
Q4 2024

A detailed history of Cwm, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Cwm, LLC holds 14,177 shares of ITCI stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,177

Previous 13,274 6.8%

Holding current value

$1.82 Million

Previous $971,000 21.94%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 04, 2025	BUY	$71.19 - $91.57 $64,284 - $82,687	903 Added 6.8%	14,177 $1.18 Million
Q3 2024 Oct 08, 2024	BUY	$67.99 - $80.84 $809,216 - $962,157	11,902 Added 867.49%	13,274 $971,000
Q2 2024 Jul 09, 2024	BUY	$64.76 - $79.84 $40,539 - $49,979	626 Added 83.91%	1,372 $94,000
Q1 2024 Apr 05, 2024	BUY	$64.37 - $75.65 $23,559 - $27,687	366 Added 96.32%	746 $52,000
Q4 2023 Feb 01, 2024	BUY	$46.37 - $73.65 $4,729 - $7,512	102 Added 36.69%	380 $27,000
Q3 2023 Oct 11, 2023	SELL	$52.09 - $64.1 $3,333 - $4,102	-64 Reduced 18.71%	278 $14,000
Q2 2023 Aug 03, 2023	BUY	$54.67 - $66.44 $4,482 - $5,448	82 Added 31.54%	342 $22,000
Q1 2023 Apr 28, 2023	BUY	$43.8 - $56.99 $4,818 - $6,268	110 Added 73.33%	260 $14,000
Q4 2022 Feb 01, 2023	BUY	$44.07 - $54.45 $2,027 - $2,504	46 Added 44.23%	150 $8,000
Q3 2022 Oct 27, 2022	BUY	$42.7 - $59.99 $982 - $1,379	23 Added 28.4%	104 $5,000
Q2 2022 Jul 28, 2022	BUY	$43.0 - $65.64 $43 - $65	1 Added 1.25%	81 $5,000
Q1 2022 Apr 21, 2022	BUY	$38.74 - $62.09 $2,905 - $4,656	75 Added 1500.0%	80 $5,000
Q4 2021 Jan 31, 2022	BUY	$35.2 - $53.42 $176 - $267	5 New	5 $0

Others Institutions Holding ITCI

# of Institutions

417

Shares Held

88.5M

Call Options Held

284K

Put Options Held

105K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12.1B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account